The cancer biomarkers market is often a semi-consolidated market. To fortify their position, key market gamers are concentrating on the introduction of novel biomarker checks, and mergers & acquisitions with other well known firms using an aim to determine a strong manufacturer existence.The market is segmented into protein biomarkers, genetic biom